---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-000537"
form_type: "8-K"
ticker: "ZSQR"
cik: "0001759186"
company_name: "Z Squared Inc."
filed_at: "2025-01-24T23:59:59+00:00"
generated_at: "2026-05-27T11:21:31.825969+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Coeptis raises $1.1M convertible note and completes $10M Series A preferred stock sale

## Summary
- $1.1M convertible note to Yorkville with 8% interest, maturity Dec 31, 2025; conversion price with floor at $1.00.
- Series A preferred stock sale raises ~$10M from accredited investors at $1,000 per share.
- Preferred investors receive 13.91% non-voting equity in subsidiaries SNAP Biosciences and GEAR Therapeutics.
- Board member Christopher Calise participated in the Series A offering.
- Note includes amortization events triggering monthly payments of $250k principal plus 5% premium.

## SEC filing metadata
- accession: 0001683168-25-000537
- form_type: 8-K
- ticker: ZSQR
- cik: 0001759186
- company_name: Z Squared Inc.
- filed_at: 2025-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759186/000168316825000537/0001683168-25-000537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759186/000168316825000537/coeptis_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-000537
- JSON: https://secwatch.observer/filing/0001683168-25-000537.json
- Plain text: https://secwatch.observer/filing/0001683168-25-000537.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.